RxDoctor Payments Data

Shannon Ullman, APRN

Family · Parkersburg, WVNPI 1871102277

Payments from drug & device makers

$2,545in general payments, 2019–2025

Across 124 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$441
  • Novartis$437
  • Boehringer Ingelheim$314
  • Pfizer$235
  • E.r. Squibb & Sons, L.L.C.$229
  • Bayer$197
  • plus $691 from 11 others

What the payments were for

  • Food & beverage$2,545100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,545 in reported general payments places this provider in the 80th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$69,628
Medicare patients
438
Services billed
1,086

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$106,196
JardianceEmpagliflozin37$49,700
FarxigaDapagliflozin Propanediol48$34,286
EntrestoSacubitril/Valsartan20$25,210
Repatha SureclickEvolocumab23$15,307
VascepaIcosapent Ethyl11$7,114
Ranolazine ErRanolazine32$2,866
Isosorbide Mononitrate ErIsosorbide Mononitrate203$2,382
Metoprolol Succinate164$2,105
Amiodarone Hcl15$1,573
Nitroglycerin120$1,065
Atorvastatin Calcium113$1,059
Metoprolol Tartrate123$930
Ezetimibe38$861
Diltiazem 24hr Er (Cd)Diltiazem Hcl54$712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$235$106,196119 claims
Boehringer IngelheimJardiance$314$49,70037 claims
AstraZenecaFarxiga$441$34,28648 claims
NovartisEntresto$437$25,21020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,507 family providers in West Virginia.

Other family in Parkersburg

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →